PapersFlow Research Brief
Synthesis and Biological Evaluation
Research Guide
What is Synthesis and Biological Evaluation?
Synthesis and Biological Evaluation is the process of chemically synthesizing quinoxaline derivatives, followed by testing their antimicrobial and anticancer activities to assess potential therapeutic applications.
This field encompasses 63,530 papers focused on developing new catalysts for quinoxaline synthesis and evaluating their biological properties as antimicrobial and anticancer agents. Nitrogen heterocycles, including quinoxaline derivatives, appear in 59% of unique small-molecule U.S. FDA approved drugs, as analyzed by Vitaku et al. (2014) in "Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals".
Topic Hierarchy
Research Sub-Topics
Quinoxaline Synthesis
Researchers develop metal-catalyzed, multicomponent, and green synthetic routes to quinoxaline scaffolds from o-phenylenediamines and 1,2-dicarbonyls. They optimize catalysts, solvents, and conditions for diversity-oriented synthesis.
Antimicrobial Quinoxaline Derivatives
Studies evaluate MIC values, mechanisms like DNA gyrase inhibition, and SAR of substituted quinoxalines against Gram-positive/negative bacteria and fungi. Researchers pursue resistance-breaking hybrids.
Quinoxaline Anticancer Agents
This sub-topic assesses cytotoxicity in cell lines, topoisomerase inhibition, apoptosis induction, and kinase targeting by quinoxaline hybrids. In vivo xenograft studies validate efficacy and toxicity profiles.
Catalysts for Quinoxaline Formation
Researchers design nano, ionic liquid, and organocatalysts for regioselective quinoxaline synthesis under mild conditions. They benchmark recyclability, scope, and mechanistic pathways using spectroscopy.
Structure-Activity Relationships of Quinoxalines
Systematic modification studies correlate substituents, electronics, and lipophilicity with biological potency using QSAR modeling. Researchers identify pharmacophores for multi-target optimization.
Why It Matters
Synthesis and Biological Evaluation of quinoxaline derivatives supports medicinal chemistry by producing compounds with antimicrobial activity against pathogens and potential as anticancer agents. For instance, Purser et al. (2007) in "Fluorine in medicinal chemistry" highlight fluorinated compounds, relevant to quinoxaline modifications, with a remarkable record in providing lead compounds for therapeutic applications, cited 7252 times. Nitrogen heterocycles central to these efforts constitute 59% of unique small-molecule FDA-approved drugs, enabling treatments across pharmaceuticals as detailed by Vitaku et al. (2014). These evaluations identify candidates for clinical advancement, such as fluorine-containing drugs introduced from 2001–2011 reviewed by Wang et al. (2013).
Reading Guide
Where to Start
"Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals" by Vitaku et al. (2014), as it provides foundational data on heterocycle prevalence (59% of FDA drugs) essential for understanding quinoxaline relevance.
Key Papers Explained
Vitaku et al. (2014) in "Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals" quantifies nitrogen heterocycles at 59%, setting context for quinoxaline synthesis; Purser et al. (2007) in "Fluorine in medicinal chemistry" (7252 citations) builds by detailing fluorine's role in such compounds' medicinal success; Wang et al. (2013) in "Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)" extends to market examples; Hagmann (2008) in "The Many Roles for Fluorine in Medicinal Chemistry" connects mechanisms across evaluations.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Focus shifts to fluorine-enhanced quinoxalines in late-stage trials, as reviewed by Zhou et al. (2016) in "Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas," emphasizing new trends in heterocycle therapeutics.
Papers at a Glance
Frequently Asked Questions
What are the main focuses of Synthesis and Biological Evaluation?
It centers on synthesizing quinoxaline derivatives using new catalysts and evaluating their antimicrobial and anticancer activities. This includes heterocyclic compounds with potential medicinal applications. The field covers oxidation processes and derivative modifications for enhanced biological profiles.
How prevalent are nitrogen heterocycles in approved drugs?
Analysis reveals that 59% of unique small-molecule U.S. FDA approved drugs contain a nitrogen heterocycle. "Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals" (Vitaku et al., 2014) reports the top 25 most commonly utilized types. Quinoxalines fall within this significant structural class.
What role does fluorine play in compounds from this field?
Fluorine enhances medicinal chemistry profiles of quinoxaline derivatives, improving metabolic stability and binding. Purser et al. (2007) in "Fluorine in medicinal chemistry" document fluorinated drugs' success in therapeutics. Hagmann (2008) in "The Many Roles for Fluorine in Medicinal Chemistry" details applications in pharmaceuticals.
What methods are used for biological evaluation?
Evaluations test antimicrobial activity and anticancer potential of synthesized quinoxalines. Techniques include assays for oxidative metabolism and pathogen killing, as in Nathan et al. (1983) identifying interferon-gamma's role in macrophage activation. These confirm therapeutic viability.
Which nitrogen heterocycles are most common in drugs?
The top 25 nitrogen heterocycles are quantified in FDA-approved pharmaceuticals by Vitaku et al. (2014). These structures, including quinoxaline types, dominate small-molecule drugs at 59% prevalence. Frequency data guides synthesis priorities.
Open Research Questions
- ? How can new catalysts improve quinoxaline synthesis yields for antimicrobial derivatives?
- ? What structural modifications enhance quinoxaline anticancer selectivity?
- ? Which biological assays best predict quinoxaline clinical efficacy?
- ? How do fluorine substitutions affect quinoxaline metabolic stability in vivo?
- ? What role do nitrogen heterocycle patterns play in quinoxaline drug-receptor interactions?
Recent Trends
The field maintains 63,530 works on quinoxaline synthesis and evaluation, with persistent emphasis on nitrogen heterocycles (59% of FDA drugs per Vitaku et al., 2014) and fluorine integration, as in high-citation reviews like Purser et al. with 7252 citations.
2007No recent preprints or news in last 12 months indicate steady maturation without reported surges.
Research Synthesis and Biological Evaluation with AI
PapersFlow provides specialized AI tools for Chemistry researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Code & Data Discovery
Find datasets, code repositories, and computational tools
See how researchers in Chemistry use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Synthesis and Biological Evaluation with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Chemistry researchers